Rutgers Cancer Institute of New Jersey and RWJBarnabas Health to Showcase Novel and Expansive Hematology/Oncology Data at the 64th American Society of Hematology Annual Meeting and Exposition
News provided by
Rutgers Cancer Institute of New Jersey and RWJBarnabas HealthNov 15, 2022, 07:00 ET
The institution's latest advancements in the treatment of blood cancers will be unveiled in numerous scheduled presentations, including several oral presentations
NEW BRUNSWICK, N.J., Nov. 15, 2022 /PRNewswire/ -- Physician-scientists from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health will present a wide-ranging scope of new hematology/oncology data from their clinical research program at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, being held in New Orleans, Louisiana (and virtually) from December 10-13, 2022. A total of 24 abstracts have been accepted, comprising clinical data and analyses that advance the understanding and treatment of such blood cancers as lymphoma, leukemia and myeloma. Rutgers Cancer Institute, together with RWJBarnabas Health, is New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center and the leading cancer program in the state.
"We have a passionate team of world-class cancer specialists and researchers that is dedicated to transforming cancer care by developing novel strategies and medical advancements, including participation in close to 100 clinical trials throughout our system, all with the single goal of helping those facing a diagnosis of a blood cancer to live longer and live better," said Matthew Matasar, MD, MS, Chief of Blood Disorders at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health. "The remarkable breadth of our faculty's contribution to their fields being presented at this year's ASH Annual Meeting and Exposition affirms the strong foundation of clinical excellence, discovery and innovation that defines Rutgers Cancer Institute of New Jersey and RWJBarnabas Health as a leader in New Jersey, nationally, and globally in this new era of cancer treatment," added Dr. Matasar, who oversees the Sections of Hematologic Malignancies, Transplant and Cell Therapy, and Benign Hematology, and is also Professor of Medicine at Rutgers Robert Wood Johnson Medical School.
Highlights of the accepted abstracts include the following oral presentations:
- Development and validation of the advanced-Stage Hodgkin Lymphoma International Prognostication Index (A-HIPI). This state-of-the-art model to predict progression-free and overall survival in adults with advanced stage classical Hodgkin lymphoma by five years uses comprehensive individual patient data from international clinical trials and large prospective registries that were standardized, normalized and harmonized as part of the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium.
- Data from a multicenter phase 2 study evaluating the safety and efficacy of Polatuzumab vedotin (Pola) combined with rituximab, ifosfamide, carboplatin and etoposide (RICE) as second line treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in patients who relapse > 1 year after frontline treatment. Pola is an antibody-drug conjugate that is safe and effective when combined with chemotherapy in frontline and relapsed, transplant-ineligible DLBCL patients.
- Updated results, after a median follow up of 27 months, from a phase 2 study in which Mosunetuzumab (Mosun), a T-cell engaging bispecific monoclonal antibody (Bi-mAb), demonstrated a high rate of complete response with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who had received ≥2 prior therapies. Mosun, the first Bi-mAb approved for the treatment of patients with relapsed/refractory follicular lymphoma, is a fixed-duration treatment that can be administered in an outpatient setting.
The full list of presentations at this year's ASH Annual Meeting and Exposition follows:
Oral Presentations |
||
Abstract and Session No. |
Title |
Presentation Date/Time |
Abstract 154 |
Double Hit/Double Expressor Lymphomas: A Multicenter Analysis of |
Saturday, December 10, 2022, |
Abstract 313 |
Development and Validation of the advanced-Stage Hodgkin |
Saturday, December 10, 2022, |
Abstract 442 |
Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As |
Sunday, December 11, 2022, |
Abstract 542 |
Risk Profiling of Patients with Previously Untreated Diffuse Large |
Sunday, December 11, 2022, |
Abstract 610 |
Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with |
Sunday, December 11, 2022, |
Abstract 730 |
Brentuximab Vedotin Combined with Chemotherapy in Newly |
Monday, December 12, 2022, |
Abstract 1000 |
Consensus Cachexia Criteria Are Independently Linked to |
Monday, December 12, 2022, |
Poster Presentations |
||
Abstract and Session No. |
Title |
Presentation Date/Time |
|
(Session 618) |
Prognostic Importance of Cytogenetic Subgroups in Relapse Risk |
Saturday, December 10, 2022, |
|
(Session 621) |
Mutations of ATM Confer a Risk of Inferior Survival in Patients with |
Saturday, December 10, 2022, |
|
(Session 623) |
Population Pharmacokinetics and Exposure–Response Analyses from |
Saturday, December 10, 2022, |
|
(Session 626) |
Subcutaneous Mosunetuzumab Is Active with a Manageable Safety |
Saturday, December 10, 2022, |
|
(Session 627) |
High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, |
Saturday, December 10, 2022, |
|
(Session 621) |
Identification of Genetic Subtypes in Follicular Lymphoma |
Sunday, December 11, 2022, |
|
(Session 622) |
Pharmacodynamics and Biomarker Correlates of Imvotamab |
Sunday, December 11, 2022, |
|
(Session 623) |
Pooled Safety Analysis from Phase I–III Studies for Patients with |
Sunday, December 11, 2022, |
|
(Session 623) |
FLIPI-3: A New PET-Based Prognostic Index for Follicular Lymphoma |
Sunday, December 11, 2022, |
|
(Session 623) |
Favorable Overall Survival Following First and Second Relapse of |
Sunday, December 11, 2022, |
|
(Session 905) |
COVID-19 Infection in Children with Down Syndrome and Hematologic |
Sunday, December 11, 2022, |
|
(Session 114) |
Leg Ulcer Prevalence and Outcomes in a Real-World, Multicenter, |
Monday, December 12, 2022, |
|
(Session 603) |
Adult T-Cell Leukemia/Lymphoma Diagnosed in North American Is |
Monday, December 12, 2022, |
|
(Session 622) |
Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, |
Monday, December 12, 2022, |
|
(Session 626) |
Polatuzumab Vedotin Plus Bendamustine and Rituximab in |
Monday, December 12, 2022, |
|
(Session 653) |
Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific |
Monday, December 12, 2022, |
|
(Session 905) |
Impact of Race and Social Determinants of Health on Outcomes in |
Monday, December 12, 2022, |
About Rutgers Cancer Institute of New Jersey
As New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute, together with RWJBarnabas Health, offers the most advanced cancer treatment options, including bone marrow transplantation, proton therapy, CAR T-cell therapy and complex surgical procedures. Along with clinical trials and novel therapeutics such as precision medicine and immunotherapy – many of which are not widely available – patients have access to these cutting-edge therapies at Rutgers Cancer Institute of New Jersey in New Brunswick, Rutgers Cancer Institute of New Jersey at University Hospital in Newark, as well as through RWJBarnabas Health facilities. To make a tax-deductible gift to support the Cancer Institute of New Jersey, call 848-932-8013 or visit www.cinj.org/giving.
For journalists – contact:
Krista Didzbalis
Media Relations Specialist
732 507 8307
[email protected]
For patient appointments/inquiries – contact:
844-CANCERNJ (844-226-2376)
SOURCE Rutgers Cancer Institute of New Jersey and RWJBarnabas Health
Share this article